Drug intelligence / Profile preview

ADC2631

Development stage: Preclinical
Lead developer: Hangzhou Adcoris Biopharmaceuticals
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ADC2631 is an investigational, first-in-class antibody-drug conjugate (ADC) being developed by Hangzhou Adcoris Biopharmaceuticals for the treatment of solid tumors. The drug utilizes Adcoris's proprietary ADC technology platform to target an undisclosed tumor-associated antigen. It is currently in early-stage development, with its specific target, payload, and linker mechanisms remaining undisclosed.

Beyond the preview

Go deeper on ADC2631.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADC2631.

Explore the full profile